Locoregional Therapies for Bridging to Transplant in HCC
with Dr. Alex Kim and Dr. Christopher Beck
Interventional Radiologist Dr. Alex Kim and Dr. Christopher Beck discuss the utility of different locoregional liver therapies in bridging HCC patients to transplant.
Special thanks to our sponsor
BackTable, LLC (Producer). (2020, June 8). Ep. 67 – Locoregional Therapies for Bridging to Transplant in HCC [Audio podcast]. Retrieved from
In this Episode
Dr. Alex Kim is a practicing Interventional Radiologist at MedStar Georgetown University Hospital in Washington D.C.
Host Dr. Chris Beck is a practicing interventional radiologist with Regional Radiology Group in New Orleans.
TriSalus Infusion Systems
TriSalus Life Sciences is dedicated to improving patient outcomes in HCC and other highly intractable solid tumors. TriSalus Infusion Systems have the potential to deliver diagnostic, therapeutic, and immuno-stimulant agents directly into the tumor vascular, powered by their proprietary pressure-enabled delivery approach.
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693‐699. doi:10.1056/NEJM199603143341104 - Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394‐1403. doi:10.1053/jhep.2001.24563 - Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival
DiNorcia J, Florman SS, Haydel B, et al. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. Ann Surg. 2020;271(4):616‐624. doi:10.1097/SLA.0000000000003253 - Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma
Shi L, Wang J, Ding N, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019;10(1):5421. Published 2019 Nov 28. doi:10.1038/s41467-019-13204-3 - Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy
Kim AY, Miller A. Evaluation of Surefire's precision direct-to-tumor embolization device to augment therapeutic response to intra-arterial, liver-directed therapies for patients with primary and secondary liver cancers. Expert Rev Med Devices. 2016;13(5):435‐443. doi:10.1586/17434440.2016.1164594
Kim AY, Frantz S, Krishnan P, et al. Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System® for the treatment of hepatocellular carcinoma. PLoS One. 2017;12(9):e0183861. Published 2017 Sep 1. doi:10.1371/journal.pone.0183861
Cheng A-L, Qin S, Ikeda M, et al. IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).Ann Oncol. 2019;30(suppl 9):ix186-ix187. doi: 10.1093/annonc/mdz446.002. - IMbrave150: efficacy and safety results
National Comprehensive Cancer Network:
Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734-9. - Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma
Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164-71. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
This content is not yet available for this podcast.
Disclaimer: The Materials available on the BackTable Podcast are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
More Ways to Stay Up to Date
Get the App
Everything BackTable. All in one place. Get the free BackTable App to access exclusive intel on over 40 procedures.
Stream the Podcast
Is your media library missing a "seriously helpful advice from interventional experts" playlist? You can now listen to the BackTable podcast on these popular streaming platforms.
Keep Up With Your Peers
Get BackTable In Your Inbox